Updated:
Arm Holdings shares fell in morning trading on Thursday, October 8, as investors weighed the potential effect of its legal dispute with Qualcomm on the chip designer’s licensing revenue. Investing.com reported Arm’s American depositary receipts down 3.8% at $283.25 during the session. The five-day jury trial in Delaware, which began October 5, has Qualcomm seeking relief that could suspend royalty payments to Arm for as long as five years.
The case places a key commercial relationship under scrutiny: Arm licenses processor technology to chipmakers, including Qualcomm, which uses Arm-based designs in products such as smartphone processors. Reuters reported that the trial centers on Qualcomm’s accusations that Arm failed to provide contracted chip-testing tools. Qualcomm is also seeking a ruling that would let it stop paying royalties, a remedy that could put billions of dollars at stake, according to reporting on the proceedings.
Contract claims underpin the dispute
Qualcomm’s claims include an allegation that Arm withheld chip-testing tools required under the companies’ architecture license agreement. The disagreement concerns the obligations the parties owe one another under that contract; the allegations remain contested, and the trial had not concluded when the October 8 report was published.
Investing.com also reported that Qualcomm says Arm disclosed a 2024 threat to terminate its license to the press. Qualcomm alleges the disclosure harmed negotiations with Meta Platforms and lowered the value of a potential chip deal by about $170 million. That figure is Qualcomm’s claimed loss, not a court finding.
Separate question over future licensing terms
A related proceeding before the judge is examining whether Arm negotiated in good faith with Qualcomm over the next generation of Arm technology. The dispute is distinct from the jury’s consideration of Qualcomm’s contract claims, although both could affect the companies’ future commercial relationship.
Investing.com said testimony addressed Arm’s proposed per-chip royalty rates for a newer architecture generation, describing them as a substantial increase. The specific terms and their potential effect on either company’s revenue were not fully established in the reporting available. The case therefore involves both past contract performance and the terms on which Qualcomm may access future Arm technology.
Why the outcome matters to Arm investors
Arm’s business is built largely around licensing its processor designs and collecting royalties when customers use them. A successful bid by Qualcomm to suspend payments could create financial exposure for Arm, while a decision concerning the license relationship may also influence negotiations over future technology. The size and duration of any eventual financial impact remain uncertain until the court resolves the claims and the parties’ contract rights.
The dispute follows an earlier legal clash between the companies over Qualcomm’s use of CPU designs developed by Nuvia, which Qualcomm acquired in 2021. In 2024, a jury in that case did not reach a unanimous verdict on all questions, while finding that Qualcomm’s chips were covered by its own Arm license. That earlier case did not settle the separate contract allegations now being heard in Delaware.
Market pressure and what comes next
The stock decline also came against a weaker market backdrop. Investing.com reported the S&P 500, Nasdaq Composite and Dow Jones Industrial Average lower during the session, though Arm’s reported loss was larger. Those comparisons describe the day’s market movements; they do not establish that the trial alone caused the share-price drop.
Investing.com additionally cited a preplanned late-September sale of more than 10,000 Arm shares by the company’s chief financial officer and recent net selling by exchange-traded funds, including Invesco QQQ Trust. The publication also noted that Arm had fallen below its 20-day and 100-day moving averages. These factors provide market context, but do not independently explain investor decisions.
The jury trial was scheduled to run for five days, with a verdict potentially due by the end of the week, according to the October 8 reporting. The exact timing of a verdict and the resolution of the related bench-trial issues remained uncertain. Arm’s next earnings report was scheduled for November 4, another upcoming date for investors to watch as the legal proceedings continue.
